 |
|
Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria
Amaylia Oehadian, Prayudi Santoso, Dick Menzies, Rovina Ruslami
Tuberc Respir Dis. 2022;85(2):111-121. Published online 2022 Jan 20 DOI: https://doi.org/10.4046/trd.2021.0122
|
|
Citations to this article as recorded by
 Structural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity
Matin Shaikh, Harun Patel
Bioorganic & Medicinal Chemistry.2025; 118: 118025. CrossRef Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis
Xinxin Zhong, Ao Lin, Jian Luo, Yeqin Li, Jinlan Chen, Chao Ning, Fu Cao
Postgraduate Medical Journal.2024; 100(1184): 366. CrossRef In silico drug design strategies for discovering novel tuberculosis therapeutics
Christian S. Carnero Canales, Aline Renata Pavan, Jean Leandro dos Santos, Fernando Rogério Pavan
Expert Opinion on Drug Discovery.2024; 19(4): 471. CrossRef Incidence and risk factors of myelosuppression of linezolid in patients with drug-resistant tuberculosis: A scoping review
Oki Nugraha Putra, Telly Purnamasari
One Health Bulletin.2024; 4(1): 1. CrossRef Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
Helena I. M. Boshoff, Katherine Young, Yong-Mo Ahn, Veena D. Yadav, Brendan M. Crowley, Lihu Yang, Jing Su, Sangmi Oh, Kriti Arora, Jenna Andrews, Michelle Manikkam, Michelle Sutphin, Anthony J. Smith, Danielle M. Weiner, Michaela K. Piazza, Joel D. Fleeg
ACS Infectious Diseases.2024; 10(5): 1679. CrossRef Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients: Clinical Factors and Hematological Toxicities
Junjie Cheng, Yuan Yuan, Jinmeng Li, Ruoying Zhang, Xudong Fan, Zhirou Xu, Huirong Lin, Xinjun Cai, Mingfeng Zheng
Infection and Drug Resistance.2024; Volume 17: 2531. CrossRef Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape
Meghana N. Patel, Archita J. Patel, Manish N. Nandpal, Manan A. Raval, Ravish J. Patel, Amit A. Patel, Keshav Raj Paudel, Philip M. Hansbro, Sachin Kumar Singh, Gaurav Gupta, Kamal Dua, Samir G. Patel
Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations
Dario Cattaneo, Deborah JE Marriott, Cristina Gervasoni
Expert Review of Clinical Pharmacology.2023; 16(3): 219. CrossRef Nanosized Drug Delivery Systems to Fight Tuberculosis
Tom Bourguignon, Jesus Alfredo Godinez-Leon, Ruxandra Gref
Pharmaceutics.2023; 15(2): 393. CrossRef Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Connie A Haley, Marcos C Schechter, David Ashkin, Charles A Peloquin, J Peter Cegielski, Barbara B Andrino, Marcos Burgos, Lori A Caloia, Lisa Chen, Angel Colon-Semidey, Malini B DeSilva, Shireesha Dhanireddy, Susan E Dorman, Felicia F Dworkin, Heidi Hamm
Clinical Infectious Diseases.2023; 77(7): 1053. CrossRef Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving
Marilena Muraglia, Brigida Immacolata Pia Schiavone, Antonio Rosato, Maria Lisa Clodoveo, Filomena Corbo
Molecules.2023; 28(17): 6348. CrossRef Efficacy and Safety of Linezolid in the Treatment of Nontuberculous Mycobacterial Pulmonary Disease: A Review
Mi Seon Park, Eun Joo Choi
Drug Targets and Therapeutics.2023; 2(2): 145. CrossRef The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis
Brett D. Edwards, Stephen K. Field
Drugs.2022; 82(18): 1695. CrossRef
|